$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000165495422001646 Filed on February 14, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q3
Revenue	$216.1K	$250.0K	$159.5K
YoY Change	143.51%	-252.47%	-155.27%
Cost Of Revenue	$46.91K	$29.17K	$53.93K
YoY Change	-15.39%	-0.78%	114.01%
Gross Profit	$169.2K	$220.8K	$105.6K
YoY Change	408.06%	-214.2%	-133.64%
Gross Profit Margin	78.29%	88.33%	66.18%
Selling, General & Admin	$3.010M	$3.318M	$3.837M
YoY Change	-24.95%	-34.24%	64.55%
% of Gross Profit	1778.8%	1502.41%	3634.81%
Research & Development	$4.980M	$5.426M	$3.485M
YoY Change	98.45%	35.27%	19.18%
% of Gross Profit	2943.5%	2457.28%	3301.53%
Depreciation & Amortization	$44.09K	$27.59K	$12.56K
YoY Change	199.73%	165.03%	-6.58%
% of Gross Profit	26.06%	12.49%	11.9%
Operating Expenses	$8.037M	$8.773M	$7.375M
YoY Change	22.23%	-3.44%	101.68%
Operating Profit	-$7.820M	-$8.451M	-$7.216M
YoY Change	20.57%	-8.63%	82.89%
Interest Expense	$3.019K	$2.773K	$5.631K
YoY Change		48.21%	-24.81%
% of Operating Profit
Other Income/Expense, Net	$188.8K	-$235.3K	$103.1K
YoY Change	-75.04%	-68.29%	2119.93%
Pretax Income	-$7.632M	-$8.686M	-$7.113M
YoY Change	33.19%	-13.06%	80.49%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.632M	-$8.686M	-$7.113M
YoY Change	33.19%	-13.06%	80.49%
Net Earnings / Revenue	-3531.56%	-3474.59%	-4459.88%
Basic Earnings Per Share
Diluted Earnings Per Share	-$31.96K	-$36.46K	-$29.86K
COMMON SHARES
Basic Shares Outstanding	231.7M shares	231.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.72M	$47.33M	$53.42M
YoY Change	-45.05%	-34.41%	-38.3%
Cash & Equivalents	$37.72M	$47.33M	$53.42M
Short-Term Investments
Other Short-Term Assets	$2.705M	$2.380M	$2.947M
YoY Change	-2.01%	-6.93%	24.86%
Inventory	$1.032M	$1.079M	$1.108M
Prepaid Expenses
Receivables	$790.0K	$584.0K	$914.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$42.25M	$51.37M	$58.39M
YoY Change	-46.78%	-39.91%	-41.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$544.6K	$511.3K	$140.0K
YoY Change	-61.91%	-58.43%	-89.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$56.92K
YoY Change	-0.01%	-0.01%	-0.01%
Total Long-Term Assets	$1.570M	$1.626M	$1.343M
YoY Change	5.64%	26.38%	-2.24%
TOTAL ASSETS
Total Short-Term Assets	$42.25M	$51.37M	$58.39M
Total Long-Term Assets	$1.570M	$1.626M	$1.343M
Total Assets	$43.82M	$52.99M	$59.73M
YoY Change	-45.82%	-38.93%	-40.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.403M	$160.2K	$762.8K
YoY Change	178.09%	-86.36%	-21.47%
Accrued Expenses	$3.175M	$6.178M	$4.991M
YoY Change	-42.73%	21.98%	21.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$99.60K	$96.92K
YoY Change
Total Short-Term Liabilities	$11.98M	$13.86M	$9.788M
YoY Change	19.33%	91.24%	-22.64%
LONG-TERM LIABILITIES
Long-Term Debt	$178.1K	$204.9K	$0.00
YoY Change
Other Long-Term Liabilities	$2.955M	$3.014M	$6.168M
YoY Change	-62.87%	-74.23%	-46.51%
Total Long-Term Liabilities	$2.955M	$3.014M	$6.168M
YoY Change	-62.87%	-74.23%	-46.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.98M	$13.86M	$9.788M
Total Long-Term Liabilities	$2.955M	$3.014M	$6.168M
Total Liabilities	$15.73M	$17.80M	$16.76M
YoY Change	-12.58%	-6.04%	-30.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$375.2M	-$367.6M	-$358.9M
YoY Change
Common Stock	$2.318M	$2.317M	$2.313M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.09M	$35.20M	$42.97M
YoY Change
Total Liabilities & Shareholders Equity	$43.82M	$52.99M	$59.73M
YoY Change	-45.82%	-38.93%	-40.95%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q3
OPERATING ACTIVITIES
Net Income	-$7.632M	-$8.686M	-$7.113M
YoY Change	33.19%	-13.06%	80.49%
Depreciation, Depletion And Amortization	$44.09K	$27.59K	$12.56K
YoY Change	199.73%	165.03%	-6.58%
Cash From Operating Activities	-$9.491M	-$6.289M	-$6.424M
YoY Change	170.84%	-56.39%	-268.47%
INVESTING ACTIVITIES
Capital Expenditures	-$77.40K	-$89.10K	-$57.76K
YoY Change	1253.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$77.40K	-$89.10K	-$57.76K
YoY Change	1253.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-37.13K	282.3K	-$202.4K
YoY Change	705.42%	-2606.66%	160.21%
NET CHANGE
Cash From Operating Activities	-9.491M	-6.289M	-$6.424M
Cash From Investing Activities	-77.40K	-89.10K	-$57.76K
Cash From Financing Activities	-37.13K	282.3K	-$202.4K
Net Change In Cash	-9.606M	-6.096M	-$6.684M
YoY Change	173.3%	-57.76%	-278.94%
FREE CASH FLOW
Cash From Operating Activities	-$9.491M	-$6.289M	-$6.424M
Capital Expenditures	-$77.40K	-$89.10K	-$57.76K
Free Cash Flow	-$9.414M	-$6.200M	-$6.366M
YoY Change	169.07%	-57.01%	-266.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	231695273	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47325547	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60104919	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	583991	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1580443	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1078896	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	1162000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2379693	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3059679	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	51368127	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	65907041	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	511316	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94817	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1058241	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1237813	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	USD
CY2021Q4	us-gaap	Assets Assets	52994600	USD
CY2021Q2	us-gaap	Assets Assets	67296587	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	160180	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	640650	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6178200	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5797378	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	360655	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	351853	USD
CY2021Q4	ptn	Short Term Finance Lease Liabilities ShortTermFinanceLeaseLiabilities	96924	USD
CY2021Q2	ptn	Short Term Finance Lease Liabilities ShortTermFinanceLeaseLiabilities	0	USD
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	1563	USD
CY2020Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	4800	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	399146232	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-367594492	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-351795397	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35196307	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52994600	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67296587	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7068033	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3721907	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13863992	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10511788	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	715893	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	900520	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	204908	USD
CY2021Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3013500	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6232907	USD
CY2021Q4	us-gaap	Liabilities Liabilities	17798293	USD
CY2021Q2	us-gaap	Liabilities Liabilities	17645215	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	40	USD
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231695273	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	230049691	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2316953	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	2300497	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400473806	USD
CY2021Q4	ptn	Product Revenue Net ProductRevenueNet	72140	USD
CY2020Q4	ptn	Product Revenue Net ProductRevenueNet	-163971	USD
CY2021Q4	ptn	License And Contract LicenseAndContract	250000	USD
CY2020Q4	ptn	License And Contract LicenseAndContract	0	USD
	ptn	License And Contract LicenseAndContract	250000	USD
	ptn	License And Contract LicenseAndContract	0	USD
CY2021Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29171	USD
CY2020Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29400	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	83104	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	54600	USD
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5426397	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4011418	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8911161	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6935269	USD
CY2021Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3317760	USD
CY2020Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5044913	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7154302	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7376519	USD
CY2021Q4	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2020Q4	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-1623795	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2973	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	16935	USD
CY2021Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-234078	USD
CY2020Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-745002	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-126719	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-745002	USD
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-235288	USD
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-742073	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-132150	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-737427	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-8686476	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9991775	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15799095	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13932551	USD
CY2021Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2021Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	238276793	shares
CY2020Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	236405065	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	238256318	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	236375463	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	42969127	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	623441	USD
CY2021Q4	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-5917	USD
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	280000	USD
CY2021Q4	ptn	Option Exercises Amount OptionExercisesAmount	16132	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-8686476	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	49651372	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1256168	USD
	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-208270	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	280000	USD
	ptn	Option Exercises Amount OptionExercisesAmount	16132	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15799095	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35196307	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	76975481	USD
CY2020Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	862683	USD
CY2020Q4	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-11263	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9991775	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	80172849	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1683857	USD
	ptn	Taxes Withheld Related To Restricted Stock Units TaxesWithheldRelatedToRestrictedStockUnits	-89029	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13932551	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	67835126	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40154	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23854	USD
	ptn	Gain On Termination Agreement GainOnTerminationAgreement	0	USD
	ptn	Gain On Termination Agreement GainOnTerminationAgreement	10376205	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	179572	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	152447	USD
	ptn	Unrealized Foreign Currency Transaction Loss UnrealizedForeignCurrencyTransactionLoss	-126719	USD
	ptn	Unrealized Foreign Currency Transaction Loss UnrealizedForeignCurrencyTransactionLoss	-745002	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1256168	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1683857	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-996452	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	446623	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-679986	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1818695	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-83104	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	213293	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-480470	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	458821	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	380822	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-399536	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-175825	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-145167	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	7091452	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12712413	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10607131	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	146862	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-146862	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	208270	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	89029	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	280000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16132	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	79903	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-89029	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-12779372	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10696160	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60104919	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82852270	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47325547	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72156110	USD
	us-gaap	Interest Paid Net InterestPaidNet	8404	USD
	us-gaap	Interest Paid Net InterestPaidNet	9360	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-367594492	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-8686476	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15799095	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47325547	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13863992	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2544120	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2503966	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong> (2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and six months ended December 31, 2021 may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2021, filed with the U.S. Securities and Exchange Commission (“SEC”), which includes consolidated financial statements as of June 30, 2021 and 2020 and for the fiscal years then ended.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4	ptn	Description Of Finance Lease DescriptionOfFinanceLease	lease obligations for two new finance leases, each with a term of three years.
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	47053506	USD
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	59730428	USD
CY2021Q4	ptn	Property And Equipment PropertyAndEquipment	309791	USD
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	6798625	shares
	ptn	Accrued Expenses AccruedExpenses	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>Accrued Expenses –</em> Third parties perform a significant portion of the Company’s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p>
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	18194000	USD
	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	2300000	USD
CY2021Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	242706	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	54854	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	84094	USD
CY2021Q4	ptn	Accrued Expenses Inventory Purchases AccruedExpensesInventoryPurchases	1917633	USD
CY2021Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27828623	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37207984	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	7123500	shares
CY2020Q3	ptn	Contract Termination Agreement Payments ContractTerminationAgreementPayments	12000000	USD
CY2021Q1	ptn	Contract Termination Agreement Payments ContractTerminationAgreementPayments	4300000	USD
CY2021Q4	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	1163489	USD
CY2020Q3	ptn	Inventory And Prepaid Expenses Estimated Fair Value InventoryAndPrepaidExpensesEstimatedFairValue	5817795	USD
	ptn	Gain On License Termination Agreement GainOnLicenseTerminationAgreement	1623795	USD
	us-gaap	Loss On Contract Termination LossOnContractTermination	4407987	USD
CY2021Q2	ptn	Net Loss NetLoss	2784192	USD
	ptn	Agreement With Fosun AgreementWithFosun	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Development Co. Ltd. (“Fosun”) for exclusive rights to commercialize Vyleesi in China (the “Fosun License Agreement”). Under the terms of the agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense. The Company will receive a $7,500,000 milestone payment when regulatory approval in China is obtained, provided that a commercial supply agreement for Vyleesi has been entered into. Palatin has the potential to receive up to $92,500,000 in additional sales related milestone payments and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun. For the three and six months ended December 31, 2021, the Company recorded $250,000 of license and contract revenue from the Fosun License Agreement. </p>
CY2017Q4	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	USD
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	USD
CY2017Q4	ptn	Taxexpenses taxexpenses	500000	USD
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	92500000	USD
CY2021Q4	us-gaap	Revenues Revenues	250000	USD
CY2017Q4	us-gaap	Officers Compensation OfficersCompensation	417500	USD
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	USD
CY2017Q4	ptn	Taxexpenses taxexpenses	82500	USD
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	3000000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	37500000	USD
CY2021Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	569370	USD
CY2021Q4	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	36352	USD
CY2021Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	454750	USD
CY2021Q4	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	229365	USD
CY2021Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	259468	USD
CY2021Q4	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	1200000	USD
CY2021Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	1200000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	913976	USD
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1145461	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2379693	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3059679	USD
CY2021Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	47053506	USD
CY2021Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	59730428	USD
CY2021Q4	ptn	Clinical Study Costs ClinicalStudyCosts	1898088	USD
CY2021Q2	ptn	Clinical Study Costs ClinicalStudyCosts	778705	USD
CY2021Q2	ptn	Accrued Expenses Inventory Purchases AccruedExpensesInventoryPurchases	2340000	USD
CY2021Q4	ptn	Accrued Selling Expenses AccruedSellingExpenses	1027073	USD
CY2021Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	1839724	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	117063	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	185485	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6178200	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5797378	USD
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	11049033	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7068033	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3013500	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3721907	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6232907	USD
	ptn	Decription Of Commission DecriptionOfCommission	The Company pays Canaccord 3.0% of the gross proceeds as a commission.
CY2021Q4	ptn	Company Received CompanyReceived	280000	USD
CY2021Q4	ptn	Common Stock Share Issued CommonStockShareIssued	350000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.80
CY2021Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	380735	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	779547	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	955785	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21882500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y2M12D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1034273	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	103150	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	118152	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.70
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	43600	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	73349	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.70
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21750549	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	373722	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	13571910	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.75
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	370833	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8178639	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M6D
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValue	2889	USD
	ptn	Unvested Performance Based Restricted Stock UnvestedPerformanceBasedRestrictedStock	1605573	USD
	ptn	Unvested Performance Based Restricted Stock UnvestedPerformanceBasedRestrictedStock	332785	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	476621	USD
CY2020Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	388720	USD
	us-gaap	Restricted Stock Expense RestrictedStockExpense	728072	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	14840762	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	81117	shares
	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-1624158	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	13135487	shares
	ptn	Vested Shares Not Issued VestedSharesNotIssued	7123500	USD
CY2021Q2	ptn	Performance Based Restricted Stock PerformanceBasedRestrictedStock	450000	shares
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.00
	ptn	Vesting Of Restricted Share VestingOfRestrictedShare	372176	shares
	ptn	Aggregate Value AggregateValue	208270	USD

Files In Submission

Name	View Source	Status
0001654954-22-001646-index-headers.html	Edgar Link	pending
0001654954-22-001646-index.html	Edgar Link	pending
0001654954-22-001646.txt	Edgar Link	pending
0001654954-22-001646-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20211231.xsd	Edgar Link	pending
ptn-20211231_cal.xml	Edgar Link	unprocessable
ptn-20211231_def.xml	Edgar Link	unprocessable
ptn-20211231_lab.xml	Edgar Link	unprocessable
ptn-20211231_pre.xml	Edgar Link	unprocessable
ptn_10q.htm	Edgar Link	pending
ptn_10qimg4.jpg	Edgar Link	pending
ptn_10qimg5.jpg	Edgar Link	pending
ptn_10q_htm.xml	Edgar Link	completed
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2022 Q1 Form 10-Q Financial Statement

#000165495422001646 Filed on February 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2022 Q1 Form 10-Q Financial Statement

#000165495422001646 Filed on February 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn